Takeda, Mederi Therapeutics & more — 6 GI company key notes

Written by Eric Oliver | November 08, 2017 | Print  |

Here are six updates on GI companies from the past week:

A study, published in the Indian Journal of Gastroenterology, examined the safety and efficacy of Mederi Therapeutics' Stretta Therapy in treating gastroesophageal reflux disease.

Vizient bestowed its 2017 Innovative Technology designation on Teleflex's LMA Gastro Airway medical device.

Motus GI presented results of a study evaluating the performance of its Pure-Vu System at the 25th UEG Week, Oct. 28 to Nov. 1 in Barcelona, Spain.

The Colon Cancer Alliance changed its name to the Colorectal Cancer Alliance.

IM HealthScience announced results of its "Functional Dyspepsia Adherence and Compliance Trial" for its FDgard product.

Studies, presented at the 25th UEG Week, demonstrated the effectiveness of Takeda's Entyvio in treating ulcerative colitis and Crohn's disease, IBD News Today reported.

More articles on gastroenterology: 
GI leader to know: Dr. Clark Harrison of Gastroenterology Consultants
Stock market week-in-review for 5 large GI companies — Oct. 30-Nov. 3
What the ACA changed about colorectal cancer — 3 study insights

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.